These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 23546445)
41. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of TOPCAT Trial. Merrill M; Sweitzer NK; Lindenfeld J; Kao DP JACC Heart Fail; 2019 Mar; 7(3):228-238. PubMed ID: 30819379 [TBL] [Abstract][Full Text] [Related]
42. Aldosterone antagonism and myocardial infarction: from animals to man and back. Solomon SD; Pfeffer MA J Am Coll Cardiol; 2003 Nov; 42(9):1674-6. PubMed ID: 14607458 [No Abstract] [Full Text] [Related]
43. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT. Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918 [TBL] [Abstract][Full Text] [Related]
44. [Mineralocorticoid receptor antagonist spironolactone improves left ventricular remodeling in patients with congestive heart failure and acute myocardial infarction]. Tsutamoto T Nihon Yakurigaku Zasshi; 2004 Aug; 124(2):90-100. PubMed ID: 15277727 [TBL] [Abstract][Full Text] [Related]
45. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. Mak GJ; Ledwidge MT; Watson CJ; Phelan DM; Dawkins IR; Murphy NF; Patle AK; Baugh JA; McDonald KM J Am Coll Cardiol; 2009 Oct; 54(18):1674-82. PubMed ID: 19850207 [TBL] [Abstract][Full Text] [Related]
46. Aldosterone Antagonism in Atrial Fibrillation: Implications for AF-Predominant HFpEF. Ho JE J Am Heart Assoc; 2020 Sep; 9(18):e018396. PubMed ID: 32909522 [No Abstract] [Full Text] [Related]
47. [Misdiagnosed emergency: heart failure symptoms after infarct. Rapid aldosterone block can safe the tired heart]. MMW Fortschr Med; 2008 May; 150(22):48-9. PubMed ID: 18700263 [No Abstract] [Full Text] [Related]
48. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Tannenbaum S; Sayer GT Curr Opin Cardiol; 2015 May; 30(3):250-8. PubMed ID: 25807227 [TBL] [Abstract][Full Text] [Related]
49. More hope for heart failure. Findings suggest expanded use of aldosterone-blockers. Aaronson K Health News; 2003 May; 9(5):4. PubMed ID: 12739453 [No Abstract] [Full Text] [Related]
50. Eplerenone for the treatment of cardiovascular disorders. Watanabe M; Krum H Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915 [TBL] [Abstract][Full Text] [Related]
51. Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT Trial. Anand IS; Claggett B; Liu J; Shah AM; Rector TS; Shah SJ; Desai AS; O'Meara E; Fleg JL; Pfeffer MA; Pitt B; Solomon SD JACC Heart Fail; 2017 Apr; 5(4):241-252. PubMed ID: 28359411 [TBL] [Abstract][Full Text] [Related]
52. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement]. Kolloch R; Offers E MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033 [TBL] [Abstract][Full Text] [Related]